March 12, 2020 / 7:30 AM / 19 days ago

BRIEF-Astrazeneca Updates On Phase III GY004 Trial For Cediranib

March 12 (Reuters) - AstraZeneca PLC:

* ASTRAZENECA PLC - UPDATE ON PHASE III GY004 TRIAL FOR CEDIRANIB

* ASTRAZENECA - UPDATE ON PHASE III GY004 TRIAL FOR CEDIRANIB ADDED TO LYNPARZA IN PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER

* ASTRAZENECA - TRIAL DID NOT MEET PRIMARY ENDPOINT OF PROGRESSION- FREE SURVIVAL VERSUS. PLATINUM-BASED CHEMOTHERAPY

* ASTRAZENECA - SAFETY AND TOLERABILITY PROFILES OBSERVED IN GY004 WERE GENERALLY CONSISTENT WITH THOSE KNOWN FOR EACH MEDICINE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below